Celldex (CLDX) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 906.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -30.25%
• EPS Growth: -9.70%
• Country: US
• Employees: 186
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,406,550
• 10 Day Avg. Volume: 836,232
• 30 Day Avg. Volume: 906,500
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $49.20
• Price Target Upside: 107.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $28.00 ▲(17.99% Upside)

Celldex's stock score is primarily impacted by its weak financial performance, with persistent losses and cash flow challenges. While technical indicators suggest a positive market trend, the company's negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative Product Development

The development of Barzolvolimab, showing efficacy in chronic spontaneous urticaria, highlights Celldex's innovative capabilities in immunotherapy, potentially leading to new revenue streams and strengthening its market position in the biotechnology sector.

Strong Gross Profit Margin

A high gross profit margin indicates efficient production and cost management, providing a buffer against operational losses and allowing reinvestment into R&D, crucial for long-term growth in the biotech industry.

Low Leverage Risk

Minimal leverage risk enhances financial stability, allowing Celldex to focus on strategic R&D investments without the burden of high debt, supporting sustainable growth and operational flexibility.

Negative Factors

Declining Revenue Trend

A declining revenue trend poses significant challenges to Celldex's financial health, potentially limiting its ability to fund R&D and impacting its competitive position in the biotech market.

Persistent Losses

Persistent losses and negative margins indicate operational inefficiencies, which could hinder Celldex's ability to achieve profitability and sustain long-term growth without strategic improvements.

Weak Cash Flow Generation

Weak cash flow generation limits Celldex's ability to invest in R&D and new product development, potentially affecting its innovation pipeline and long-term competitiveness in the biotech industry.

Celldex Business Overview & Revenue Model

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

How the Company Makes Money

Celldex generates revenue through several key streams, primarily from the development and commercialization of its therapeutic products. The company may earn revenue from product sales once its therapies receive regulatory approval and are marketed. Additionally, Celldex often engages in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments as development progresses, and royalties on sales once products are commercialized. These partnerships are critical for funding research and development efforts and expanding market reach. Grant funding and research contracts may also contribute to its earnings, although product sales and collaborations remain the primary sources of revenue.

Celldex Financial Statement Overview

Summary

Celldex shows modest revenue growth but faces substantial losses with negative net income and EBIT margins. The balance sheet is strong with a high equity ratio and minimal leverage, but cash flow is challenged with negative free cash flow, indicating reliance on external funding.

Income Statement

Celldex shows modest revenue growth with a 7.7% increase in the most recent TTM period. However, the company is struggling with substantial losses, as evidenced by negative net income and EBIT margins. The gross profit margin remains positive at 78.6%, but the net profit margin is significantly negative at -2366.6%, indicating the company is not yet profitable. The biotechnology industry often experiences prolonged periods of negative earnings due to high R&D expenses.

Balance Sheet

The balance sheet is relatively strong with a high equity ratio of 95.1%, which denotes a solid capital structure. The debt-to-equity ratio is very low at 0.005, suggesting minimal leverage. Despite these strengths, the company is facing consistent net losses, impacting its return on equity, which stands at -25.4% in the TTM period.

Cash Flow

Celldex's cash flow is challenged, with a negative free cash flow of -$171.9 million in the TTM period. The operating cash flow to net income ratio is slightly positive at 0.96, indicating some alignment with reported losses. However, the free cash flow to net income ratio is negative, reflecting operational cash burn. Positive financing cash flow suggests reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.79M	7.02M	6.88M	2.36M	4.65M	7.42M
Gross Profit	4.97M	7.02M	-111.13M	-79.90M	1.58M	-35.12M
EBITDA	-231.40M	-191.90M	-139.03M	-104.20M	-66.08M	-45.64M
Net Income	-199.61M	-157.86M	-141.43M	-112.33M	-70.51M	-59.78M
Balance Sheet
Total Assets	692.41M	792.34M	465.63M	352.74M	444.65M	235.84M
Cash, Cash Equivalents and Short-Term Investments	630.34M	725.28M	423.60M	304.95M	408.25M	194.42M
Total Debt	3.03M	3.81M	2.54M	4.03M	3.04M	3.48M
Total Liabilities	37.00M	45.34M	36.46M	26.53M	25.18M	26.48M
Stockholders Equity	655.41M	747.00M	429.17M	326.20M	419.48M	209.36M
Cash Flow
Free Cash Flow	-187.06M	-159.70M	-109.11M	-105.56M	-62.16M	-41.96M
Operating Cash Flow	-186.19M	-157.78M	-107.29M	-103.73M	-60.91M	-40.40M
Investing Cash Flow	164.60M	-290.13M	-105.78M	89.94M	-216.16M	-98.22M
Financing Cash Flow	1.89M	441.45M	218.46M	4.08M	272.37M	171.23M

Celldex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Negative. The current price of 23.73 is below the 20-day moving average (MA) of 26.47, below the 50-day MA of 25.39, and above the 200-day MA of 22.09, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 37.38 is Neutral, neither overbought nor oversold. The STOCH value of 7.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDX.

Celldex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JANX	55 Neutral	$1.62B	-15.33	-12.82%	―	-97.10%	-96.30%
TVTX	54 Neutral	$3.05B	―	-410.78%	―	114.22%	77.02%
VRDN	52 Neutral	$2.10B	-5.29	-62.99%	―	5.90%	-0.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLDX	51 Neutral	$1.58B	―	-27.17%	―	-30.25%	-9.70%
ETNB	42 Neutral	―	―	-86.86%	―	―	-82.75%
VERA	39 Underperform	$1.55B	-6.73	-54.83%	―	―	-62.51%

Celldex Corporate Events

Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study

Study Overview: Celldex Therapeutics is conducting a Phase 2 clinical trial titled ‘A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis.’ The study aims to evaluate the effectiveness and safety of barzolvolimab in treating prurigo nodularis, a chronic skin condition characterized by itchy nodules. This research is significant as it could lead to a new treatment option for patients suffering from this debilitating condition.

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria

Study Overview: Celldex Therapeutics is conducting a Phase 3 study titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)’. The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to current antihistamine treatments.

Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment

Celldex Therapeutics is conducting a Phase 3 clinical trial titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)’. The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to standard H1-antihistamine treatments.

Celldex Halts Barzolvolimab Development for EoE

On August 19, 2025, Celldex Therapeutics announced results from its Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). The study met its primary endpoint by demonstrating significant mast cell depletion in the gastrointestinal tract. However, this did not translate into improved clinical outcomes, leading Celldex to halt further development of barzolvolimab for EoE. The company remains committed to advancing barzolvolimab in other conditions where mast cells play a crucial role, such as chronic urticaria and atopic dermatitis.

The most recent analyst rating on (CLDX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.

Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. In its latest earnings report for the quarter ending June 30, 2025, Celldex reported a significant increase in research and development expenses, reflecting its ongoing commitment to advancing its drug candidates, particularly barzolvolimab, across multiple mast cell-driven diseases. The company’s total revenues decreased compared to the previous year, primarily due to reduced contract and grant income, while operating losses widened as a result of increased investment in research and development. Despite the financial losses, Celldex maintains a strong cash position, with $630.3 million in cash, cash equivalents, and marketable securities, ensuring its ability to fund operations for at least the next twelve months. Looking forward, Celldex aims to continue its focus on advancing its clinical programs and exploring strategic partnerships to support its long-term growth and development goals.

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria

Study Overview: Celldex Therapeutics is conducting a Phase 3 study titled A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1). The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to standard H1-antihistamine treatments.

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Spontaneous Urticaria

Celldex Therapeutics is conducting a Phase 3 study titled A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1). The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to standard H1-antihistamine treatments.

Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria

Celldex Therapeutics is conducting a Phase 3 study titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)’. The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to H1-antihistamines.

Celldex Therapeutics’ Phase 3 Study: A Potential Breakthrough for Chronic Urticaria

Study Overview: Celldex Therapeutics is conducting a Phase 3 study titled A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2). The study aims to evaluate the efficacy, safety, and tolerability of barzolvolimab in adults with Chronic Spontaneous Urticaria (CSU) who do not respond adequately to standard H1-antihistamines. This study is significant as it targets a population with limited treatment options, potentially offering a new therapeutic pathway.

Celldex Therapeutics’ Promising Phase 2 Study on Barzolvolimab for Prurigo Nodularis

Celldex Therapeutics is conducting a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis. The study aims to evaluate the effectiveness and safety of barzolvolimab in adults suffering from prurigo nodularis, a chronic skin condition characterized by itchy nodules.